2 active not recruiting, 2 completed, 2 recruiting. 3 Phase 2, 2 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Hormone Receptor Positive: new trials by email Literature Review of Hormone Receptor Positive trials Research Report on Hormone Receptor Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer Patritumab deruxtecan, Trastuzumab deruxtecan - Hormone Receptor Positive, HER2-low or HER2-ultralow | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 220 | 2026-09-17 | 2026-10-01 |
| Ablation Compare With Surgery for Early Breast Cancer breast conserving surgery, cryo-thermal ablation - Breast Cancer, Early Stage | Not applicable | Recruiting | Peking University People's Hospital | 264 | 2026-01-01 | 2026-03-19 |
| Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib Neratinib, Loperamide, Colesevelam - Early-stage Breast Cancer, HER2 Positive Breast Cancer | Phase 2 | Active not recruiting | Spanish Breast Cancer Research Group | 177 | 2022-08-31 | 2025-04-01 |
| First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors NP137 DL and RP2D - Advanced Solid Tumor, Endometrial Carcinoma | Phase 1 | Completed | Centre Leon Berard | 70 | 2017-01-09 | 2022-07-25 |
| A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer Palbociclib, Tamoxifen, Fulvestrant - Metastatic Breast Cancer, Hormone Receptor Positive | Phase 2 | Completed | University of California, San Francisco | 70 | 2015-10-19 | 2022-03-16 |
| Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Anastrozole, Exemestane, Laboratory Biomarker Analysis - Breast Adenocarcinoma, Hormone Receptor Positive | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 10273 | 2006-04-07 | 2026-10-01 |
Breast Neoplasms (5) · Endometrial Neoplasms (1)
Neoplasms (6) · Neoplasms by Site (6) · Breast Diseases (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Uterine Diseases (1) · Uterine Neoplasms (1)
Tamoxifen (2) · Anastrozole (1) · Colesevelam Hydrochloride (1) · Fulvestrant (1) · Letrozole (1) · Loperamide (1) · Mastectomy, Segmental (1) · Radiation (1) · Radiotherapy (1) · exemestane (1) · neratinib (1) · palbociclib (1) · patritumab deruxtecan (1) · trastuzumab deruxtecan (1)
Centre Leon Berard (1) · Daiichi Sankyo (1) · National Cancer Institute (NCI) (1) · Peking University People's Hospital (1) · Spanish Breast Cancer Research Group (1) · University of California, San Francisco (1)
United States (3) · France (2) · Spain (2) · Australia (1) · Belgium (1) · Canada (1) · China (1) · Ireland (1) · Italy (1) · Japan (1) · New Zealand (1) · Peru (1) · Puerto Rico (1) · South Korea (1) · Taiwan (1)
Hope S Rugo, MD (1) · Joseph A Sparano (1)
PMID 26412349, PMID 29860917, PMID 31157962, PMID 31409130, PMID 31566680, PMID 32271671, PMID 33626896, PMID 34090143, PMID 34137783, PMID 34470826, PMID 35175284, PMID 37043210, PMID 37532929
2015 (1), 2019 (1), U10CA021115 (1), U10CA180820 (1)